Drug Development

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A Phase 1 trial launch is more than a milestone; it's a look at the future of pharma, where AI-driven speed and strategic global partnerships converge.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.

FloBiotech and UCLA Health are betting on a new strategy against neurodegeneration: boosting the brain's own defenses. This alliance could redefine a field long plagued by failure.

New data on elecoglipron, an oral pill with no food restrictions, shows major weight loss and A1C reduction, positioning AstraZeneca to disrupt the GLP-1 market.

New data on Eli Lilly's oral GLP-1, orforglipron, shows superior results over rivals, promising a new era for millions of needle-averse patients.

Eikon Therapeutics adds a consumer goods giant to its board, a move signaling a strategic pivot from pure science to global commercialization.

Septerna's novel oral drug for hypoparathyroidism could end the tyranny of injections and supplements, but its success hinges on a bigger bet: a new system for drugging life's most difficult molecular targets.

Promising early data for obesity drug DA-1726 shows rapid weight loss, while vanoglipel demonstrates powerful synergy in MASH and diabetes combination therapies.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?